Discovery of high-affinity peptide ligands for vancomycin
Related Experiment Video
Updated: Jul 7, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Nianhuan Yao1, Chun-Yi Wu, Wenwu Xiao
1Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Cancer Center, University of California, Davis, Sacramento, CA 95817, USA.
Abstract:
Vancomycin, an important antibiotic against medically relevant gram-positive bacteria such as methicillin-resistant Staphylococcus aureus, exerts its antibacterial effects by binding with moderate affinity to the C-terminal Lys-D-Ala-D-Ala motif (Kaa) of the bacterial cell wall peptide precursor. Essential for Kaa binding to vancomcyin is the free-carboxyl group on the terminal D-Ala in Kaa. In efforts to identify other Kaa-based peptides which bind vancomycin with higher affinity, we utilized our one-bead-one-compound (OBOC) combinatorial library approach, a method which has been widely used to discover highly specific ligands against various receptors. In standard OBOC peptide libraries, the C-terminal end of the synthesized peptide is tethered to a solid-support/resin, however, this study reports development of a synthetic strategy for generating OBOC peptide libraries with a free D-Ala-D-Ala carboxyl end. We screened these "OBOC inverted" peptide libraries against vancomycin, and discovered a series of peptide ligands with strong consensus, which bind vancomycin. To further optimize these ligands, two highly focused Kaa-containing OBOC combinatorial peptidomimetic libraries were designed, synthesized, and screened against vancomycin under more stringent conditions. Peptidomimetic ligands which bind vancomycin with higher affinity than Kaa were identified. The dissociation constant of one of these ligands, Lys(Ac)-HOCit-Glu-Cha-Lys(3,5-dihydroxybenzoyl)-D-Ala-D-Ala (9), as determined by surface plasmon resonance, was 1.03 microM, roughly a 50-fold improvement in affinity compared to Kaa (K(D) = 50 microM).
Insights
Researchers developed novel "OBOC inverted" peptide libraries to discover vancomycin ligands. They identified peptidomimetics with significantly higher binding affinity than the natural Kaa target, improving vancomycin
Area of Science:
- Medicinal Chemistry
- Microbiology
- Drug Discovery
Background:
- Vancomycin is a critical antibiotic for Gram-positive bacteria, including MRSA.
- Its antibacterial action relies on binding the Lys-D-Ala-D-Ala (Kaa) motif of bacterial cell wall precursors.
- A free carboxyl group on the terminal D-Ala of Kaa is essential for vancomycin binding.
Purpose of the Study:
- To develop a novel synthetic strategy for one-bead-one-compound (OBOC) peptide libraries with free carboxyl ends.
- To discover novel Kaa-based peptide ligands that bind vancomycin with higher affinity.
- To optimize lead compounds through focused peptidomimetic libraries.
Main Methods:
- Development of "OBOC inverted" combinatorial peptide libraries with free D-Ala-D-Ala carboxyl termini.
- Screening of these libraries against vancomycin to identify binding ligands.
- Design, synthesis, and screening of focused peptidomimetic libraries for enhanced affinity.
Main Results:
- Identification of novel peptide ligands that bind vancomycin.
- Discovery of peptidomimetic ligands exhibiting higher binding affinity than Kaa.
- A lead peptidomimetic ligand demonstrated a 50-fold increase in binding affinity (K(D) = 1.03 µM) compared to Kaa (K(D) = 50 µM).
Conclusions:
- The "OBOC inverted" library approach is effective for discovering high-affinity vancomycin ligands.
- Optimized peptidomimetics show potential for improved vancomycin-based therapeutics.
- This strategy advances the development of novel antibiotics targeting resistant bacteria.
More Related Videos
13:49Semi-automated Biopanning of Bacterial Display Libraries for Peptide Affinity Reagent Discovery and Analysis of Resulting Isolates
Published on: December 6, 2017
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020